Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
An update from GlaxoSmithKline ( (GB:GSK) ) is now available.
GSK has announced that the European Medicines Agency has accepted their application for depemokimab, a new ultra-long-acting biologic for asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps (CRSwNP). If approved, it will be the first of its kind with a 6-month dosing schedule. The submission is supported by positive results from the SWIFT and ANCHOR trials, which demonstrated depemokimab’s effectiveness in reducing asthma exacerbations and nasal polyp size. This innovation could significantly impact the treatment landscape by providing sustained disease inhibition with fewer doses, thereby addressing patient adherence challenges and reducing healthcare burdens.
More about GlaxoSmithKline
GSK is a global biopharmaceutical company focused on advancing respiratory medicine and developing next-generation treatments for a range of respiratory diseases. With a portfolio that includes vaccines, biologics, and inhaled medicines, GSK aims to enhance outcomes for people with various respiratory conditions, including asthma and chronic obstructive pulmonary disease (COPD).
YTD Price Performance: 4.12%
Average Trading Volume: 7,959,773
Technical Sentiment Consensus Rating: Sell
Current Market Cap: £55.35B
See more insights into GSK stock on TipRanks’ Stock Analysis page.
